1. Home
  2. NGVT vs SNDX Comparison

NGVT vs SNDX Comparison

Compare NGVT & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ingevity Corporation

NGVT

Ingevity Corporation

HOLD

Current Price

$72.27

Market Cap

2.1B

Sector

Industrials

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$20.58

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGVT
SNDX
Founded
1964
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.8B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
NGVT
SNDX
Price
$72.27
$20.58
Analyst Decision
Buy
Strong Buy
Analyst Count
2
13
Target Price
$67.50
$80.23
AVG Volume (30 Days)
287.7K
1.2M
Earning Date
02-18-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,382,100,000.00
$111,304,000.00
Revenue This Year
N/A
$617.40
Revenue Next Year
$2.35
$115.70
P/E Ratio
N/A
N/A
Revenue Growth
5.63
595.65
52 Week Low
$28.49
$8.58
52 Week High
$73.20
$22.73

Technical Indicators

Market Signals
Indicator
NGVT
SNDX
Relative Strength Index (RSI) 74.10 49.06
Support Level $63.56 $19.99
Resistance Level $69.80 $21.89
Average True Range (ATR) 2.34 1.05
MACD 0.05 -0.05
Stochastic Oscillator 90.46 35.21

Price Performance

Historical Comparison
NGVT
SNDX

About NGVT Ingevity Corporation

Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: